Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
暂无分享,去创建一个
Raffaella Barone | Françoise Borson-Chazot | François Jamar | Stanislas Pauwels | L. Kvols | S. Walrand | R. Valkema | E. Krenning | F. Jamar | F. Borson‐Chazot | S. Pauwels | Roelf Valkema | Stéphan Walrand | Larry K Kvols | Eric P Krenning | R. Barone
[1] P Lambin,et al. Low-dose hypersensitivity: current status and possible mechanisms. , 2001, International journal of radiation oncology, biology, physics.
[2] David M. Goldenberg,et al. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.
[3] S. Shen,et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] S. Weiner,et al. End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.
[5] H. Herzog,et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.
[6] M. Konijnenberg,et al. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.
[7] D. Piwnica-Worms. MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine , 1996 .
[8] Marion de Jong,et al. Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. , 2004, Cancer biotherapy & radiopharmaceuticals.
[9] G. Denardo,et al. Prediction of myelotoxicity using semi-quantitative marrow image scores. , 1997, Journal of Nuclear Medicine.
[10] K. Eckerman,et al. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] M. Cremonesi,et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Henry I. Kohn,et al. Sources, Effects and Risks of Ionizing Radiation , 1989 .
[13] H. V. van Boven,et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[15] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[16] L. Kvols,et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[17] A. Todd-Pokropek,et al. Scatter correction in scintigraphy: the state of the art , 1994, European Journal of Nuclear Medicine.
[18] M. Béhé,et al. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. , 2002, Cancer biotherapy & radiopharmaceuticals.
[19] E. Nitzsche,et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] M. Cremonesi,et al. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group , 2002 .
[21] L. Travaini,et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-Octreotide: Implications for internal radiotherapy with 90Y-DOTATOC , 2000 .
[22] S. Walrand,et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Y. Erdi,et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.
[24] H. Saji,et al. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. , 1998, Bioconjugate chemistry.
[25] J. Mueller‐Brand,et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.
[26] George Sgouros,et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] M. Stabin. Developments in the internal dosimetry of radiopharmaceuticals. , 2003, Radiation protection dosimetry.
[28] R. Valkema,et al. Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[29] F. Orsi,et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC , 1999, European Journal of Nuclear Medicine.
[30] S. Finch. Radiation-induced leukemia. , 2001, Blood.
[31] L. Kvols,et al. Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study , 2001 .
[32] H. Herzog,et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[33] K. Eckerman,et al. Evolution and status of bone and marrow dose models. , 2002, Cancer biotherapy & radiopharmaceuticals.
[34] L. Kvols,et al. Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy. , 2000 .
[35] M. Mihatsch,et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] A. Eberle,et al. Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.
[37] 岩崎 民子. SOURCES AND EFFECTS OF IONIZING RADIATION : United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes , 2002 .
[38] M G Stabin,et al. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] Larson,et al. Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[40] R. Valkema,et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.